IXICO PLC's (LON:IXI) Giulio Cerroni and Lammert Albers speak to Proactive London's Andrew Scott following the release of its first half trading update and news it's secured a “substantial new contract” for a late-phase open label study into Huntington’s disease.
They add they're expecting to report revenue growth of “at least 25%” year-on-year for the six months ended 31 March.